4,073 Shares in Doximity, Inc. (NASDAQ:DOCS) Bought by Hardy Reed LLC

Hardy Reed LLC bought a new position in Doximity, Inc. (NASDAQ:DOCS - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 4,073 shares of the company's stock, valued at approximately $217,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Global Retirement Partners LLC grew its holdings in shares of Doximity by 468.1% during the fourth quarter. Global Retirement Partners LLC now owns 534 shares of the company's stock valued at $29,000 after buying an additional 440 shares during the last quarter. UMB Bank n.a. lifted its position in Doximity by 69.1% in the 4th quarter. UMB Bank n.a. now owns 575 shares of the company's stock valued at $31,000 after acquiring an additional 235 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in Doximity by 324.2% during the 3rd quarter. Farther Finance Advisors LLC now owns 789 shares of the company's stock valued at $34,000 after purchasing an additional 603 shares during the last quarter. Morse Asset Management Inc bought a new stake in Doximity during the 3rd quarter worth approximately $46,000. Finally, Covestor Ltd raised its stake in shares of Doximity by 441.9% in the third quarter. Covestor Ltd now owns 1,680 shares of the company's stock worth $73,000 after purchasing an additional 1,370 shares during the last quarter. 87.19% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on DOCS shares. The Goldman Sachs Group lifted their target price on Doximity from $58.00 to $80.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Bank of America upped their target price on shares of Doximity from $54.00 to $57.00 and gave the stock a "neutral" rating in a research note on Monday, January 6th. Piper Sandler raised shares of Doximity from a "neutral" rating to an "overweight" rating and raised their price target for the company from $31.00 to $78.00 in a research report on Friday, February 7th. Raymond James restated an "outperform" rating and set a $83.00 price target (up from $65.00) on shares of Doximity in a report on Friday, February 7th. Finally, Stephens began coverage on shares of Doximity in a research note on Friday, December 20th. They issued an "equal weight" rating and a $55.00 price objective for the company. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Doximity presently has a consensus rating of "Moderate Buy" and a consensus price target of $64.22.

Insider Buying and Selling

In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the sale, the director now owns 6,360 shares in the company, valued at $366,463.20. This represents a 75.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 37.40% of the stock is owned by insiders.

Doximity Price Performance

NASDAQ:DOCS traded down $2.75 on Friday, reaching $72.25. 3,202,946 shares of the company's stock were exchanged, compared to its average volume of 2,419,548. The stock has a fifty day simple moving average of $60.19 and a 200-day simple moving average of $49.05. Doximity, Inc. has a 52 week low of $22.96 and a 52 week high of $85.21. The firm has a market cap of $13.49 billion, a price-to-earnings ratio of 72.25, a P/E/G ratio of 4.20 and a beta of 1.39.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.